Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline Review, H2 2019’, provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Clostridium difficile Associated Disease)

– The report reviews pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics and enlists all their major and minor projects

– The report assesses Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Absynth Biologics Ltd

Acurx Pharmaceuticals LLC

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Aviex Technologies LLC

AzurRx BioPharma Inc

Biomica

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Chain Biotechnology Ltd

Crestone Inc

CSA Biotechnologies LLC

Daiichi Sankyo Co Ltd

Deinove SAS

Enterobiotix Ltd

Facile Therapeutics Inc

Ferring International Center SA

Finch Therapeutics Group

Fzata Inc

GlaxoSmithKline Plc

Immune Biosolutions Inc

ImmuneBiotech AB

ImmuniMed Inc

ImmunoBiology Ltd

Immuron Ltd

Inositec AG

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Integrated BioTherapeutics Inc

Kaleido Biosciences Inc

KamTek Inc

KoBioLabs Inc

Locus Biosciences Inc

Mapp Biopharmaceutical Inc

Matrivax Research & Development Corp

Merck & Co Inc

MGB Biopharma Ltd

Microbiotica Ltd

Micropharm Ltd

Miyarisan Pharmaceutical Company Ltd

MyBiotics Pharma Ltd

Novabiotics Ltd

NovoBiotic Pharmaceuticals LLC

Nubiyota LLC

Oragenics Inc

Otsuka Holdings Co Ltd

PanTheryx Inc

Pfizer Inc

Procarta Biosystems Ltd

Proxi Biotech IVS

Pylum Biosciences Inc

Q2 Pharma Ltd

QureTech Bio AB

Recursion Pharmaceuticals Inc

Rise Therapeutics LLC

SciBac Inc

Scioto Biosciences Inc

Seres Therapeutics Inc

Serometrix LLC

Servatus Ltd

Summit Therapeutics Plc

Symbiotic Health Inc

Synthetic Biologics Inc

Valevia UK Ltd

Valneva SE

Vedanta Biosciences Inc

Vitality Biopharma Inc

XBiotech Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview 6

Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Development 7

Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Assessment 22

Clostridium difficile Infections (Clostridium difficile Associated Disease) Companies Involved in Therapeutics Development 30

Clostridium difficile Infections (Clostridium difficile Associated Disease) Drug Profiles 49

Clostridium difficile Infections (Clostridium difficile Associated Disease) Dormant Projects 184

Clostridium difficile Infections (Clostridium difficile Associated Disease) Discontinued Products 189

Clostridium difficile Infections (Clostridium difficile Associated Disease) Product Development Milestones 190

Appendix 200

List of Tables

“List of Tables

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, H2 2019 (Contd..2), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, H2 2019 (Contd..3), H2 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports